Biologics and Biosimilars in Oncology

With many patents about to expire in coming years, the field of biologics in oncology is about to change dramatically. Biologics are predicted to comprise over one-quarter of the pharmaceutical market by 2020. Currently, almost half of all biologics sales come from 11 major agents. All of these will have their patent expire in the […]